Selective Neuronal Nitric Oxide Synthase Inhibitors with Azole Substituents

Selective Neuronal Oxide Synthase Inhibitors for Treatment of Neurodegenerative Diseases NU 2009-164 Inventors James M. Kraus Richard B. Silverman* Short Description Nitric oxide synthase inhibitors specific to the neuronal isoform for treatment of neurodegenerative treatment without dangerous side effects Abstract Oxidative stress caused by excess nitric oxide (NO) has been implicated in several diseases, including Parkinson's and cerebral palsy. Inhibitors of the enzyme that catalyses the production of NO in neuronal tissues, neuronal nitric oxide synthase (nNOS), could have protective properties. The inhibition of the enzyme must be restricted to neuronal tissues to avoid dangerous side effects in other tissues, including an increase in blood pressure. Northwestern inventors have identified non-peptide compounds that selectively inhibit the neuronal form of NOS and successfully penetrate the blood-brain barrier. These compounds have the potential to alleviate nitric oxide excess in the brain and other neural tissues, relieving oxidative stress and reducing cell death. Since the enzymatic activity is not altered in non-target tissues, dangerous side effects are avoided. These compounds have therapeutic implications for a variety of neurodegenerative conditions. Applications o Treatment of neurodegenerative conditions Advantages o No dangerous side effects of generalized nitric oxide synthase inhibition o Enhanced bioavailability to target tissues IP Status A patent application has been filed. Marketing Contact Allan Nader, PhD Invention Manager (e) [email protected] (p) 847.491.4456